CXCR6 is required for antitumor efficacy of intratumoral CD8+ T cell.
Wang B, Wang Y, Sun X, Deng G, Huang W, Wu X, Gu Y, Tian Z, Fan Z, Xu Q, Chen H, Sun Y.
Wang B, et al. Among authors: xu q.
J Immunother Cancer. 2021 Aug;9(8):e003100. doi: 10.1136/jitc-2021-003100.
J Immunother Cancer. 2021.
PMID: 34462326
Free PMC article.